Nisa Investment Advisors
LCTX icon

Nisa Investment Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

Nisa Investment Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.08K Hold
1,589
– – ﹤0.01% 2748
2026
Q1 		$2.51K Hold
1,589
– – ﹤0.01% 2582
2025
Q4 		$2.65K Hold
1,589
– – ﹤0.01% 2567
2025
Q3 		$2.69K Hold
1,589
– – ﹤0.01% 2558
2025
Q2 		$1.44K Buy
1,589
+661
+71% +$392 ﹤0.01% 2670
2025
Q1 		$419 Sell
928
-565
-38% -$331 ﹤0.01% 2833
2024
Q4 		$750 Buy
1,493
+1,248
+509% +$916 ﹤0.01% 2739
2024
Q3 		$222 Sell
245
-391
-61% -$362 ﹤0.01% 2837
2024
Q2 		$634 Buy
+636
New +$702 ﹤0.01% 2634

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Nisa Investment Advisors's LCTX Position: Q2 2026 in Review

Nisa Investment Advisors held its Lineage Cell Therapeutics (LCTX) position steady in Q2 2026 at 1,589 shares worth $2.08K. The position accounts for ﹤0.01% of the portfolio, ranked #2748.

Nisa Investment Advisors first reported a position in LCTX in Q2 2024 and has held it in 9 quarters since. The position peaked at $2.69K in Q3 2025. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Nisa Investment Advisors held 1,589 shares of Lineage Cell Therapeutics worth $2.08K as of Q2 2026.
  • Nisa Investment Advisors left its Lineage Cell Therapeutics share count unchanged in Q2 2026.
  • Lineage Cell Therapeutics made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q2 2026, its #2748 holding.
  • Nisa Investment Advisors first reported a position in Lineage Cell Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • Nisa Investment Advisors's Lineage Cell Therapeutics position peaked at $2.69K in Q3 2025.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Nisa Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.